Dr. Robin Kate Kelley is an Associate Professor of Clinical Medicine in the Department of Medicine at the University of California, San Francisco (UCSF) and the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). Her clinical focus is on the treatment of primary liver cancers, including hepatocellular carcinoma, cholangiocarcinoma, and gall bladder carcinoma.
Kelley's research interests include developing and conducting clinical trials to identify new treatments for hepatocellular carcinoma and bile duct cancers, along with translational research on patient biospecimens to identify biomarkers of treatment response and prognosis. She has authored numerous publications reporting on treatment outcomes of novel targeted therapies and immunotherapies for hepatobiliary cancers.
Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She also completed a fellowship in hematology and oncology at UCSF. Kelley received the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009 and the ASCO Young Investigator Award in 2010. She now serves as the Co-Chair of the Gastrointestinal Oncology Site Committee for the UCSF HDFCCC and leads the clinical research program in hepatobiliary cancers, including clinical trials in hepatocellular carcinoma and cholangiocarcinoma and the UCSF Hepatobiliary Tissue Bank and Registry. She is the Chair of the UCSF HDFCCC Data and Safety Monitoring Committee. She also serves as the Chair of the Cholangiocarcinoma Foundation’s Scientific and Medical Advisory Board and is a member of the Hepatobiliary Cancers Panel of the National Comprehensive Cancer Network, the National Cancer Institute’s Hepatobiliary Cancer Task Force, and the International Liver Cancer Association Education Committee.